Table 1 Pairwise odds ratios for posts mentioning herpes zoster associated with tofacitinib and gastrointestinal perforation associated with tocilizumab versus other medications used for rheumatoid arthritis

 Tofacitinib vs. infliximab

22 vs. 405

2.45 (1.59–3.77)

 Tofacitinib vs. golimumab

22 vs. 23

2.34 (1.30–4.21)

 Tofacitinib vs. rituximab

22 vs. 120

2.03 (1.29–3.20)

 Tofacitinib vs. adalimumab

22 vs. 613

1.82 (1.19–2.79)

 Tofacitinib vs. etanercept

22 vs. 446

1.67 (1.09-2.57)

 Tocilizumab vs. rituximab

13 vs 7

12.62 (5.03 – 31.64)

 Tocilizumab vs. adalimumab

13 vs. 59

6.85 (3.76 – 12.51)

 Tocilizumab vs. infliximab

13 vs 60

5.99 (3.29 – 10.92)

 Tocilizumab vs. abatacept

13 vs. 6

5.23 (1.99 – 13.79)

 Tocilizumab vs. certolizumab

13 vs. 10

3.47 (1.52 – 7.93)